BBAR vs IBOC

BBAR exhibits weak financial health with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite strong long-term price appreciation, the stock trades at a premium valuation (P/E 30.28 vs sector avg 21.03) while facing sharp declines in revenue (-17.70% YoY) and earnings (-75.5% YoY). Earnings quality is poor, with 3 of the last 4 quarters missing estimates by an average of -45.13%, and key metrics like ROE (7.19%) and ROA (1.11%) remain below industry benchmarks. The lack of Altman Z-Score data raises transparency concerns, but the deterministic scorecard and deteriorating trends support a bearish outlook.

IBOC presents a stable but stagnant profile, characterized by a Piotroski F-Score of 4/9, indicating baseline financial health. While the stock is fundamentally undervalued relative to its Graham Number of $88.26 and analyst target of $87.00, it is hampered by negative year-over-year earnings growth (-7.60%) and a bearish technical trend score of 10/100. The company maintains strong profitability margins and a very sustainable dividend payout, but lacks the growth catalysts necessary for a bullish rating.